Aug. 29, 2023
This Q&A features Daniel B. F. Saris, M.D., Ph.D., an orthopedic surgeon specializing in knee surgery with a focus on cell-based surgical regenerative medicine at Mayo Clinic's campus in Minnesota. Here, he explains a regenerative medicine procedure for joint restoration that he believes addresses an unmet need. Dr. Saris discusses its background and future, and appropriate referral candidates.
A team of Mayo Clinic orthopedic and regenerative medicine researchers has continued development and testing of a knee joint restoration procedure, called recycled cartilage auto/allo implantation (RECLAIM). I brought RECLAIM with me from the University Medical Center Utrecht in the Netherlands, where we developed this procedure and called it IMPACT.
In this procedure, we debride the patient's knee defect. We remove cartilage from the knee or hip, mincing these pieces into smaller fragments and extracting cartilage cells through chemical digestion to the level of the chondron. We combine these recycled autologous chondrons with allogeneic donor mesenchymal stem cells (MSCs). The mixture of 10% to 20% of the patient's cells with 80% to 90% MSCs is placed into fibrin glue, which allows the surgeon to inject them into the patient's knee defect. This procedure enables the patient's body to repair the cartilage defect, something it otherwise would be unable to do.
RECLAIM is a one-stage innovative procedure for hip and knee that enables tissue growth and restoration of cartilage in the patient's joint. Within one year, the defect is filled. DNA analysis has shown this to be patient-derived new cartilage tissue without donor DNA remaining. I see it as the MSCs providing both immune modulatory signals as well as growth factor, reminding the cartilage to grow. Ultimately, RECLAIM may help preserve the joint by filling the "pothole" for a better "drive."
We have learned that combining native cartilage cells and allogeneic MSCs can be a good partnership. We consider the transplant successful if the joint is still viable in 13 to 20 years.
A depiction of the steps in the process of recycled cartilage auto/allo implantation (RECLAIM) knee cartilage regeneration.
[This animation shows RECLAIM knee cartilage regeneration. It is playing with no audio.]
RECLAIM for hip and knee is performed under FDA scrutiny as an investigational new drug in a phase 1 trial I led with a team of Mayo Clinic investigators, and it is not yet widely available. The trial began in September 2018 and ends in September 2024.
Indications for this therapy are precise. The patient must meet the following criteria:
Often, these cartilage defects are from trauma or athletic injury.
One of my biggest drivers is improving quality of life. People need to move in their lives and they need their joints to work. Patients' alternatives are usually to deal with discomfort or quit sports. We want to help them return to sports or their pre-injury lifestyles.
I am also passionate about helping patients with arthritis, one of the biggest quality-of-life threats.
My research team specifically is seeking solutions to treat defects in young patients with active lifestyles. This is a growing group, and age limits are changing. Someday, if people live to age 120, we need joint preservation solutions for individuals ages 30 to 60 and older.
We hope it will work with other joints, but that has not been studied yet. The need seems greatest for hip and knee, but we would like to explore hand, ankle, elbow and others.
We also hope RECLAIM will apply to the meniscus. We have a Ph.D. program working on that potential application.
Aaron J. Krych, M.D., an orthopedic surgeon at Mayo Clinic in Minnesota, is leading a phase 1 RECLAIM study in the hip joint. It's open for patient enrollment. We are doing a randomized controlled trial in the Netherlands for permission to enter this as standard of care.
Lucienne Vonk, Ph.D., and I developed the idea from the first experiments through completing the initial human trials. Dr. Vonk serves as a senior researcher in the Department of Orthopaedics, University Medical Center Utrecht, the Netherlands, and director of musculoskeletal diseases at Xintela AB, a biomedical company in Sweden. As we were working with RECLAIM in the Netherlands, evidence and international enthusiasm grew. It was showing promise. Mayo Clinic orthopedic and regenerative medicine leadership gave us the opportunity to continue developing RECLAIM using Mayo Clinic's stem cell bank and conduct U.S. RECLAIM clinical trials.
Also important to me was that Mayo Clinic had orthopedic surgeons who could perform the RECLAIM procedure and that Mayo had the brand respect needed to make a clinical trial happen in the U.S.
First, we will take good care of your patients. Second, it is a cell-based cartilage repair in a single surgical procedure and only available at Mayo Clinic in Minnesota in the U.S. Outside of the United States, it's also available at University Medical Center Utrecht.
If patients have cartilage defects, say, in the knee, they often have pain and swelling clinically, and the defect can be visible on MRI. Mayo Clinic has a specialized cartilage clinic. In the knee clinic, we jointly analyze those injuries with the whole team to develop one-visit solutions.
Mayo Clinic also has world leaders in orthopedic injectable therapy if our experts deem injectables best for patients' injuries.
We also have significant multidisciplinary expertise available at Mayo Clinic and have numerous clinical trials to offer.
If you have a question regarding sending a patient to Mayo Clinic, contact knee@mayo.edu or cartilage@mayo.edu.
We attempted a moonshot effort to put all elements of this procedure into one arthroscopic surgery, an important goal for our team. To now see that come to fruition after some years is exciting and rewarding for the team, and hopefully it is a valuable improvement for our patients.
Ultimately, we want RECLAIM to be available widely for many patients and to be able to apply this cell-cell combination for other joint challenges and even other organs.
Clinical trials: REcycled CartiLage Auto/Allo Implantation. Mayo Clinic.
Refer a patient to Mayo Clinic.
Here is the original post:
Mayo Clinic offers unique regenerative medicine procedure for knee and ...
- Regenerative Medicine to the Rescue - Cleveland Clinic - September 13th, 2024
- Regenerative medicine applications: An overview of clinical trials - September 13th, 2024
- The Progression of Regenerative Medicine and its Impact on Therapy ... - September 13th, 2024
- Immune cell injection significantly boosts healing of bone, muscle & skin - September 13th, 2024
- Regenerative Medicine Foundation - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT ... - September 13th, 2024
- Tissue engineering and regenerative medicine approaches in colorectal ... - September 13th, 2024
- Tubular scaffolds boost stem cell-driven bone regeneration in skull defects - Phys.org - September 13th, 2024
- Finding the right path(way) to reduce fat accumulation in the liver - Medical University of South Carolina - September 13th, 2024
- NAMRU EURAFCENT Signs Agreement with Egypt Center for Research and Regenerative Medicine - DVIDS - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program - StockTitan - September 13th, 2024
- BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and... - September 13th, 2024
- Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate - Yahoo Finance - September 13th, 2024
- Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets - Nature.com - September 13th, 2024
- Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H) - Business Wire - September 13th, 2024
- HepaTx Enters Collaboration with Mayo Clinic to Advance Cell Therapy Technology for Liver Disease to Clinical Trials - Longview News-Journal - September 13th, 2024
- Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma -... - September 4th, 2024
- Regenerative Medicine in Orthopedic Surgery: Expanding Our Toolbox - Cureus - September 4th, 2024
- Somite.ai takes pre-seed to $10M as it eyes to become the OpenAI of stem cell biology - CTech - September 4th, 2024
- Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) - Yahoo... - September 4th, 2024
- Study Explores Potential Of 3D Printed Regenerative Breast Implants - Forbes - September 4th, 2024
- Nikon Announces New Image Analysis Functions to Empower Drug Discovery Research for Cancer, Neurological Disease, and Regenerative Medicine - PR... - September 4th, 2024
- Trinity researcher scores 800,000 to boost regenerative medicine - SiliconRepublic.com - September 4th, 2024
- Seeing the future: Zebrafish regenerates fully functional photoreceptor cells and restores its vision - EurekAlert - September 4th, 2024
- Regenerative Medicine Industry Projected to Surge to USD 73,084.2 Million by 2033, Growing at an 18.5% CAGR - Future Market Insights - September 4th, 2024
- What is regenerative medicine? | Northwell Health - July 2nd, 2024
- Science Saturday: A regenerative reset for aging - July 2nd, 2024
- Science Saturday: A year of new directions and advancements for ... - March 29th, 2024
- Diverse ways regenerative medicine is advancing health care - March 29th, 2024
- Stem cell-based regenerative medicine - PMC - National Center for ... - February 27th, 2024
- Regenerative medicine | NIST - February 10th, 2024
- San Jose blood stem cell donor meets 15-year-old whose life he saved in Los Angeles - The Mercury News - May 17th, 2023
- Regenerative medicine: Current therapies and future directions - April 23rd, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - April 23rd, 2023
- Important Patient and Consumer Information About Regenerative Medicine ... - April 23rd, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 23rd, 2023
- About Regenerative Medicine - Center for Regenerative ... - Mayo Clinic - April 7th, 2023
- Regenerative Medicine | National Institutes of Health (NIH) - April 7th, 2023
- Porcine Vaccine Market is estimated to be US$ 4.41 billion by 2030 with a CAGR of 7.50%during the forecast - EIN News - April 7th, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 21st, 2023
- Active Wound Care Market Rising demand for Skin Substitutes to boost the industry (2023-2033) | CAGR of 5.5% - EIN News - March 21st, 2023
- Veterinary Orthopedic Implants Market is estimated to be 421.3 Million by 2029 with a CAGR of 5.3% - By PMI - EIN News - March 21st, 2023
- ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical... - February 8th, 2023
- A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field - Yahoo Finance - October 15th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 15th, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 15th, 2022
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 15th, 2022
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 15th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - GlobeNewswire - October 15th, 2022
- Discover Medical Advances in Cellular Therapy Research Using Cord Blood for Cancer, HIV, Cerebral Palsy and Autism During World Cord Blood Day 2022 -... - October 15th, 2022
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 15th, 2022
- Cell therapy weekly: Ray Therapeutics and Forge Biologics expand partnership - RegMedNet - October 15th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 15th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Business Wire - October 15th, 2022
- The Health Benefits Of Sea Moss, According To Experts - Forbes - October 15th, 2022
- ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of ... - The Bakersfield Californian - October 15th, 2022
- Pain Management & Regenerative Medicine Specialists DFW - September 4th, 2022
- Tissue Engineering and Regenerative Medicine - National Institute of ... - September 4th, 2022
- First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov) - September 4th, 2022
- International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review - September 4th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - September 4th, 2022
- Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace - September 4th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 4th, 2022
- TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all... - September 4th, 2022
- Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire - September 4th, 2022
- Can the immortal jellyfish teach us how to reverse aging? - Earth.com - September 4th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - September 4th, 2022
- Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - PR Newswire - September 4th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 4th, 2022
- Regenerative Medicine Partnering 2015 to 2022: Terms and Agreements Entered Into by the Leading Companies Worldwide - ResearchAndMarkets.com -... - August 19th, 2022
- Pain Relief Treatments: The Benefits of Regenerative Medicine From Head to Toe - 30Seconds.com - August 19th, 2022
- FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich... - August 19th, 2022
- Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert - August 19th, 2022
- Osteoarthritis In The Hip Or Knee? Regenerative Medicine Revolutionizes Your Treatment - Nation World News - August 19th, 2022
- 3D Systems Announces Appointment of Dr. Toby Cosgrove and Dr. Bon Ku as Members of its Medical Advisory Board - Yahoo Finance - August 19th, 2022
- Many stem cell lines used for research and therapies carry large number of mutations, Cambridge researchers find - Cambridge Independent - August 19th, 2022
- RECELL System Data to be Presented at the Controversies and Conversations in Laser & ... - The Bakersfield Californian - August 19th, 2022
- Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO - GlobeNewswire - August 19th, 2022
- Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma - Precision Oncology News - August 19th, 2022
- Column: My summer research experience at Charles R. Drew University for Medicine and Science - Los Angeles Times - August 19th, 2022
Tags: